TrialOncotarget2017

Interim analysis of a phase I/IIa trial assessing E39+GM-CSF, a folate binding protein vaccine, to prevent recurrence in ovarian and endometrial cancer patients.

Doreen O Jackson et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.